Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tipiracil hydrochloride

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and… Expand
Is this relevant?
2016
2016
SummaryBackground Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
BACKGROUND The combination drug TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine and tipiracil… Expand
Is this relevant?
2016
2016
TAS‐102, a novel oral antitumor agent, consists of trifluridine and tipiracil hydrochloride (molar ratio, 1:0.5). We investigated… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
TAS-102 is a novel oral nucleoside antitumor agent that consists of trifluridine (FTD) and tipiracil hydrochloride (TPI) at a… Expand
  • figure 1
  • figure 2
  • table I
  • table II
  • figure 3
Is this relevant?
2015
2015
TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
2015
2015
SummaryBackground TAS-102 is a nucleoside antitumor agent consisting of trifluridine (FTD) and tipiracil hydrochloride (TPI). We… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
PurposeTrifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine (FTD) and the thymidine phosphorylase inhibitor… Expand
  • table I
  • table II
  • figure 1
  • table III
  • table IV
Is this relevant?
Highly Cited
2014
Highly Cited
2014
TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI). The compound… Expand
  • table I
  • table II
  • figure 2
  • figure 1
  • table III
Is this relevant?